Teva Drives Positive Impact in Response to COVID-19 Pandemic

Teva has continuously worked since the early days of the COVID-19 pandemic to support efforts of governments and health services to curb the impact of the virus. Our global manufacturing network has been tirelessly focused on securing and scaling production of both API and finished doses for potential treatments that may prove essential in treating the condition nearly everywhere Teva does business. Recently this effort included enabling tablets and API manufactured in our Goa, India plant to be retrieved in a timely way so to be able to expand access to the medicine globally. Teva is grateful to the Indian, US and Israeli governments for taking extraordinary measures to ensure this shipment will be distributed to those who need it. Teva will continue to work with governments and international organizations throughout the world to support emerging needs related to this crisis, while doing everything possible to also continue to supply our vast portfolio of medicines to other patients.

Cautionary Note Regarding Forward-Looking Statements

This statement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the Company's COVID-19 measures, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to:

• uncertainty of the magnitude, duration, geographic reach and impact of the COVID-19 outbreak on our business and on the economy in general; the current, and uncertain future, impact of the COVID-19 outbreak on our business, financial condition, operations, cash flows, and liquidity; the adequacy or effectiveness of steps we have taken or may take to respond to the COVID-19 outbreak;
• our business and operations in general, including manufacturing or quality control problems; interruptions in our supply chain, including due to potential effects of the COVID-19 outbreak on our operations and business in geographic locations impacted by the outbreak and on the business operations of our customers and suppliers; our ability to successfully execute and maintain the activities and efforts related to the  COVID-19 measures over the long term and associated costs therewith; challenges associated with conducting business globally, including adverse effects of the COVID-19 pandemic; costs and delays resulting from the extensive governmental regulation to which we are subject, including effects on product approval due to the COVID-19 pandemic; disruptions of information technology systems; and our ability to successfully compete in the marketplace;

and other factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2019, including in the sections captioned "Risk Factors” and “Forward Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.